Achondroplasia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Achondroplasia is an autosomal-dominant disorder caused by mutations in the type 3 receptor for a fibroblast growth factor (FGFR3). A range of distinctive physical features characterizes it. Achondroplasia can be suspected during pregnancy in the third trimester when abnormal ultrasound findings, such as limb foreshortening (in the 95th percentile) and a low nasal bridge, become evident. These findings may prompt further intra-uterine imaging. After birth, individuals with achondroplasia display clinical characteristics, including short limbs, especially in the proximal segment, a long trunk, and a narrow thorax. Generally, their birth height is within the normal range. These individuals typically have a large head with frontal bossing, potentially leading to obstetric complications during childbirth. The midface tends to be hypoplastic, indicating an endochondral growth defect at the skull's base. The hands and fingers of individuals with achondroplasia are notably short. In early life, they exhibit a trident appearance due to an inability to fully oppose the third and fourth digits. This condition also features shortened long bones with wide metaphyses, a slim, radiolucent area in the proximal femur, and a horizontal acetabular roof in antenatal radiographic images.

·       Achondroplasia arises in about 1 in every 25,000 to 30,000 individuals. That, in turn, translates into around 250,000 affected persons worldwide.

 

Thelansis’s “Achondroplasia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Achondroplasia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Achondroplasia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Achondroplasia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Achondroplasia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Achondroplasia, Achondroplasia market outlook, Achondroplasia competitive landscape, Achondroplasia market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)